Breaking News Headlines Today | Ground News

New Year’s Sale — Build a balanced news diet with 40% off Vantage

endpoints.news image

News from endpoints.news

endpoints.news’s media bias is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, AllSides, and Media Bias/Fact Check.

endpoints.news’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about endpoints.news

Where is endpoints.news located?endpoints.news's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top endpoints.news News

FDA Approves First Daily Pill for Weight Loss Treatment — REUTERS / pwu404

Business · United States

FDA Approves First Daily Pill for Weight Loss Treatment

63% Center coverage: 256 sources

The U.S. Food and Drug Administration on Monday approved the first oral medication to treat obesity — a pill version of the weight-loss drug Wegovy. The pill contains semaglutide, the same active ingredient as injectable Wegovy and Ozempic.See the Story

Sanofi to acquire hepatitis B vaccine maker Dynavax for $2.2 billion — REUTERS / ixx511

Business & Markets · United States

Sanofi to acquire hepatitis B vaccine maker Dynavax for $2.2 billion

66% Center coverage: 15 sources

Sanofi will buy U.S. vaccines company Dynavax Technologies for around $2.2 billion (1.9 billion euros), the French drugmaker said on Wednesday, a deal that will give it access to an approved hepatitis B vaccine.See the Story

What's Going On With Neurocrine Biosciences Stock Tuesday? - Neurocrine Biosciences (NASDAQ:NBIX)

San Diego · San Diego

What's Going On With Neurocrine Biosciences Stock Tuesday? - Neurocrine Biosciences (NASDAQ:NBIX)

90% Center coverage: 10 sources

Neurocrine Biosciences Inc shares fall as Phase 3 study of valbenazine for dyskinetic cerebral palsy did not meet primary endpoints.See the Story

Breaking News Topics Related to endpoints.news